BioInvent International AB (BOVNF)
4.70
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
BioInvent International Free Cash Flow (Quarterly): -6.574M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -6.574M |
| December 31, 2023 | -7.587M |
| September 30, 2023 | -9.682M |
| June 30, 2023 | -8.390M |
| March 31, 2023 | -7.872M |
| December 31, 2022 | -7.656M |
| September 30, 2022 | 17.36M |
| June 30, 2022 | -6.186M |
| March 31, 2022 | -8.866M |
| December 31, 2021 | -9.385M |
| September 30, 2021 | -6.917M |
| June 30, 2021 | -7.817M |
| March 31, 2021 | -6.153M |
| December 31, 2020 | 3.374M |
| September 30, 2020 | -4.341M |
| June 30, 2020 | -2.924M |
| March 31, 2020 | -3.682M |
| December 31, 2019 | -3.171M |
| September 30, 2019 | -2.493M |
| June 30, 2019 | -3.602M |
| March 31, 2019 | -4.419M |
| December 31, 2018 | -4.772M |
| September 30, 2018 | -3.946M |
| June 30, 2018 | -4.405M |
| March 31, 2018 | -3.611M |
| Date | Value |
|---|---|
| December 31, 2017 | -3.016M |
| September 30, 2017 | -4.035M |
| June 30, 2017 | -2.657M |
| March 31, 2017 | -1.130M |
| December 31, 2016 | -2.764M |
| September 30, 2016 | -3.179M |
| June 30, 2016 | -3.284M |
| March 31, 2016 | 0.1739M |
| December 31, 2015 | -1.305M |
| September 30, 2015 | -1.386M |
| June 30, 2015 | -3.607M |
| March 31, 2015 | -2.391M |
| December 31, 2014 | -3.748M |
| September 30, 2014 | -0.2005M |
| June 30, 2014 | -3.686M |
| March 31, 2014 | -3.556M |
| December 31, 2013 | 3.751M |
| September 30, 2013 | -2.952M |
| June 30, 2013 | -5.636M |
| March 31, 2013 | -3.565M |
| December 31, 2012 | -7.690M |
| September 30, 2012 | -5.351M |
| June 30, 2012 | -6.821M |
| March 31, 2012 | -5.324M |
| December 31, 2011 | -6.573M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-9.682M
Minimum
Sep 2023
17.36M
Maximum
Sep 2022
-4.628M
Average
-6.380M
Median
Free Cash Flow (Quarterly) Benchmarks
| Abliva AB | -0.0813M |
| Karolinska Development AB | -0.6572M |
| Calliditas Therapeutics AB | -- |
| Oncopeptides AB | -4.947M |
| Olink Holding AB | -8.282M |